- Report
- February 2026
- 250 Pages
Global
From €3963EUR$4,490USD£3,423GBP
- Report
- May 2026
- 369 Pages
Global
From €5164EUR$5,850USD£4,459GBP
- Report
- May 2026
- 582 Pages
Global
From €5164EUR$5,850USD£4,459GBP
- Report
- May 2026
- 224 Pages
Global
From €5164EUR$5,850USD£4,459GBP
- Report
- May 2026
- 193 Pages
Global
From €5164EUR$5,850USD£4,459GBP
- Report
- January 2026
- 180 Pages
Global
From €3972EUR$4,500USD£3,430GBP
- Report
- May 2025
- 185 Pages
Global
From €3972EUR$4,500USD£3,430GBP
- Report
- January 2026
- 186 Pages
Global
From €3129EUR$3,545USD£2,702GBP
€3477EUR$3,939USD£3,003GBP
- Report
- January 2026
- 180 Pages
Global
From €3129EUR$3,545USD£2,702GBP
€3477EUR$3,939USD£3,003GBP
- Report
- August 2025
- 186 Pages
Global
From €3129EUR$3,545USD£2,702GBP
€3477EUR$3,939USD£3,003GBP
- Report
- August 2025
- 182 Pages
Global
From €3129EUR$3,545USD£2,702GBP
€3477EUR$3,939USD£3,003GBP
- Report
- May 2026
- 570 Pages
Global
From €5164EUR$5,850USD£4,459GBP
- Report
- May 2026
- 284 Pages
Global
From €5164EUR$5,850USD£4,459GBP
- Report
- May 2026
- 372 Pages
Global
From €5164EUR$5,850USD£4,459GBP
- Report
- May 2026
- 273 Pages
Global
From €5164EUR$5,850USD£4,459GBP
- Report
- May 2026
- 375 Pages
Global
From €5164EUR$5,850USD£4,459GBP
- Report
- May 2026
- 273 Pages
Global
From €5164EUR$5,850USD£4,459GBP
- Report
- May 2026
- 179 Pages
Global
From €5164EUR$5,850USD£4,459GBP
- Report
- February 2026
- 250 Pages
Global
From €3963EUR$4,490USD£3,423GBP
- Report
- February 2026
- 250 Pages
Global
From €3963EUR$4,490USD£3,423GBP

Lymphoma is a type of hematological malignancy that originates in the lymphatic system. It is characterized by the uncontrolled growth of lymphocytes, a type of white blood cell. Lymphomas can be either Hodgkin's or non-Hodgkin's, and can be either indolent or aggressive. Treatment options for lymphoma include chemotherapy, radiation therapy, stem cell transplantation, and targeted therapies.
The lymphoma market is a subset of the larger hematology market, which includes treatments for a variety of blood-related diseases. The lymphoma market is driven by the increasing prevalence of the disease, as well as the development of new treatments.
Companies in the lymphoma market include AbbVie, Amgen, AstraZeneca, Bristol-Myers Squibb, Celgene, Gilead Sciences, Novartis, and Pfizer. Show Less Read more